Every now and then I get to wondering
about the different types of diabetes and if there is more to the
diagnosis than the medical community is acknowledging. With the new
guidelines from the American Diabetes Association which can be read
here (and I urge you to take time to read this), I often read this
more carefully than any other provision or discussion in the
guidelines. Then I start to look for what they may not be telling
us. In any of the discussions, they seem to like to paraphrase some
areas by saying that there is much to be determined at the clinical
level.
The definition by its very nature
leaves many questions, “Diabetes is a
group of metabolic diseases characterized by hyperglycemia resulting
from defects in insulin secretion, insulin action, or both. The
chronic hyperglycemia of diabetes is associated with long-term
damage, dysfunction, and failure of different organs, especially the
eyes, kidneys, nerves, heart, and blood vessels.”
I am using only the first part of the
long definition because I think this is where some defining needs to
be done. Yes, I agree that diabetes is a metabolic disease and maybe
a group. Why the term hyperglycemia is not defined as being a
certain measurable amount or number leaves me wondering what they are
looking for in not defining this. Certainly they have a number in
mind. Then they use chronic hyperglycemia to define what may happen
to certain organs. I can understand why some organs are missing from
the list because of the lack of conclusive studies for hearing and
cognitive decline (brain). I do question why they are not given any
mention and a statement of lack of conclusive evidence. That could
then spark studies to prove that. I suspect they are not mentioned
to avoid these studies from taking place, but why?
The classification for the last several
years has gotten more restricted and only includes four
classifications. Table one below shows the four classes.
Table 1 Etiologic classification of
diabetes mellitus:
1. Type 1 diabetes (β-cell destruction, usually leading to
absolute insulin deficiency)
1. Immune mediated
2. Idiopathic
2. Type 2 diabetes (may range from predominantly insulin
resistance with relative insulin deficiency to a predominantly
secretory defect with insulin resistance)
3. Other specific types
1. Genetic defects of β-cell function
1. MODY 3 (Chromosome 12, HNF-1α)
2. MODY 1 (Chromosome 20, HNF-4α)
3. MODY 2 (Chromosome 7, glucokinase)
4. Other very rare forms of MODY (e.g., MODY 4: Chromosome 13,
insulin promoter factor-1; MODY 6: Chromosome 2, NeuroD1; MODY 7:
Chromosome 9, carboxyl ester lipase)
5. Transient neonatal diabetes (most commonly ZAC/HYAMI imprinting
defect on 6q24)
6. Permanent neonatal diabetes (most commonly KCNJ11 gene encoding
Kir6.2 subunit of β-cell KATP channel)
7. Mitochondrial DNA
8. Others
2. Genetic defects in insulin action
1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipoatrophic diabetes
5. Others
3. Diseases of the exocrine pancreas
1. Pancreatitis
2. Trauma/pancreatectomy
3. Neoplasia
4. Cystic fibrosis
5. Hemochromatosis
6. Fibrocalculous pancreatopathy
7. Others
4. Endocrinopathies
1. Acromegaly
2. Cushing's syndrome
3. Glucagonoma
4. Pheochromocytoma
5. Hyperthyroidism
6. Somatostatinoma
7. Aldosteronoma
8. Others
5. Drug or chemical induced
1. Vacor
2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide
7. β-Adrenergic agonists
8. Thiazides
9. Dilantin
10. γ-Interferon
11. Others
6. Infections
1. Congenital rubella
2. Cytomegalovirus
3. Others
7. Uncommon forms of immune-mediated diabetes
1. “Stiff-man” syndrome
2. Anti-insulin receptor antibodies
3. Others
8. Other genetic syndromes sometimes associated with diabetes
1. Down syndrome
2. Klinefelter syndrome
3. Turner syndrome
4. Wolfram syndrome
5. Friedreich ataxia
6. Huntington chorea
7. Laurence-Moon-Biedl syndrome
8. Myotonic dystrophy
9. Porphyria
10. Prader-Willi syndrome
11. Others
4. Gestational diabetes mellitus
|
They then define the blood glucose
impairment range as “having impaired
fasting glucose (IFG) [fasting plasma glucose (FPG) levels 100 mg/dl
(5.6 mmol/l) to 125 mg/dl (6.9 mmol/l)], or impaired glucose
tolerance (IGT) [2-h values in the oral glucose tolerance test (OGTT)
of 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l)].” Then
they state that these have been referred to as having prediabetes,
but do not go on to use any other term. This is the only use of the word. They only use the term
individuals to describe these people with A1cs of 5.7% to 6.4%. They
emphasize that they are to be informed of their risks for diabetes
and cardiovascular disease. Like all good doctors, they want them
counseled about effective strategies to lower their risks.
So what is purpose of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus? Is this the end of the use of the term prediabetes and how soon can we expect another term? All good questions we will have to wait for an answer. Is it possible we may have another term or will diabetes be expanded to include this range? Even this discussion on prevention or delay of diabetes only uses the term prediabetes once. Or will it take another decade or more to make the change?
No comments:
Post a Comment